Microbot Medical (NASDAQ: MBOT) to highlight LIBERTY rollout at Roth Annual Growth Conference

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Microbot Medical Inc. furnished an 8-K to share that it will participate in the Roth Annual Growth Conference in Laguna Niguel, California from March 22-24, 2026. CEO Harel Gadot will join a live fireside Q&A on March 23, with a webcast available through the company’s website.

The company also released updated investor presentation materials, accessible online, highlighting progress with its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, moving from a limited market release that began in late 2025 toward a planned full market release at the SIR conference in April 2026.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/17/2026 - 09:27 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 17, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it will be participating in the Roth Annual Growth Conference, being held March 22-24, 2026, in Laguna Niguel, CA. Harel Gadot, CEO, President & Chairman of the Company, will present live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23, 2026, and a live webcast may be accessed via the ‘Events’ section of the Company’s website at www.microbotmedical.com. The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference.

In addition, the Company released updated presentation materials. The presentation materials may be accessed via the ‘Investors’ section, under ‘IR Resources’ and then ‘Additional Resources,’ of the Company’s website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials. The presentation materials are also furnished as Exhibit 99.2 to this Current Report on Form 8-K, and are incorporated herein by reference.

The information in this Item 7.01, and Exhibits 99.1 and 99.2, are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibits 99.1 or 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description

99.1		Press Release
99.2		Presentation Materials
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.

	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: March 17, 2026

Exhibit 99.1

Microbot Medical^®to Participate at the 38th Annual Roth Conference

Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY^® in April

HINGHAM, Mass., March 17, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23^rd. Mr. Gadot will highlight the Company’s recent achievements, and how LIBERTY is a unique and differentiated solution, addressing critical unmet healthcare needs, including physician safety and staffing issues.

The presentation will be a live webcast and may be accessed via the ‘Investors’ section on Microbot Medical’s website at https://ir.microbotmedical.com/. Additionally, Mr. Gadot will be meeting growth-oriented institutional investors and other interested parties on Monday, March 23^rd, through a series of pre-scheduled one-on-one meetings. Investors should reach out to their Roth sales representatives or contact mpolyviou@evcgroup.com to schedule a one-on-one meeting.

“We believe the ongoing progress and success of our limited market release, driven by multi-site customer traction and procedural diversity, has validated our strategy to support the full market release, which is on target for next month,” commented Mr. Gadot. “We believe the Roth conference is an ideal stage to showcase this commercial momentum and introduce our differentiated growth story to a diverse audience, to support our current position and future growth.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

IR@microbotmedical.com

Media@microbotmedical.com

Exhibit 99.2

Source: View Original Filing on SEC EDGAR

FAQ

What did Microbot Medical (MBOT) disclose in its latest 8-K filing?

Microbot Medical disclosed that it will participate in the Roth Annual Growth Conference and has released updated investor presentation materials. The filing also emphasizes its LIBERTY Endovascular Robotic System, which is progressing from limited market release toward a planned full market release in April 2026.

When and where will Microbot Medical present at the Roth Annual Growth Conference?

Microbot Medical will participate in the Roth Annual Growth Conference in Laguna Niguel, California, from March 22-24, 2026. CEO Harel Gadot will appear in a live fireside Q&A discussion at 4:00 p.m. Pacific Time on Monday, March 23, 2026, with a webcast available online.

How can investors access Microbot Medical’s Roth conference webcast and materials?

Investors can access the live webcast of Microbot Medical’s Roth conference fireside Q&A through the Events section of its website. Updated presentation materials are available in the Investors section under IR Resources and Additional Resources, providing more detail on the company’s strategy and the LIBERTY system.

What is Microbot Medical’s LIBERTY Endovascular Robotic System?

LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain, supporting more efficient and safer endovascular interventions according to the company’s materials.

What commercialization timeline did Microbot Medical outline for LIBERTY in this update?

Microbot Medical stated that it began a limited market release of LIBERTY in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026. Management believes recent multi-site traction supports this transition to broader commercialization next month.

Are the Roth conference materials in the MBOT 8-K considered filed or furnished?

The Roth conference press release and updated presentation materials are being furnished, not filed, under Item 7.01 of the Exchange Act. They are not subject to Section 18 liabilities and are not deemed admissions of materiality under the securities laws, according to the disclosure.

Filing Exhibits & Attachments

41 documents